Skip to content

Newsroom

type
year
reltype
Illustration image.png

Orion’s near-term climate targets approved by the Science Based Targets initiative

9/30/2024 Press release
Illustration image.png

Orion’s collaboration partner Bayer submits application to U.S. FDA for third indication of darolutamide which has become the first ever Orion-originated blockbuster

9/26/2024 Press release
Illustration image.png

Orion and Aitia enter AI-Driven Drug Discovery and Drug Simulation Collaboration in Oncology

9/25/2024 Press release
Illustration image.png

213,285 Orion Corporation A shares converted into B shares

9/20/2024 Stock exchange release
Illustration image.png

Darolutamide plus androgen deprivation therapy significantly reduced the risk of radiological progression or death by 46% compared to placebo plus ADT in patients with metastatic hormone-sensitive prostate cancer

9/16/2024 Press release
Illustration image.png

Inside information: Orion upgrades full-year outlook for 2024

9/11/2024 Stock exchange release
Illustration image.png

Orion Corporation: Managers’ transactions – Satu Ahomäki

8/22/2024 Managers transactions
Illustration image.png

Orion Corporation: Managers’ transactions – Niclas Lindstedt

8/21/2024 Managers transactions
Illustration image.png

Orion Corporation: Managers’ transactions – Liisa Hurme

8/20/2024 Managers transactions
Illustration image.png

Orion Corporation: Managers’ transactions – Hao Pan

8/15/2024 Managers transactions
Illustration image.png

44,767 Orion Corporation A shares converted into B shares

8/14/2024 Stock exchange release
Illustration image.png

Orion Corporation: Managers’ transactions – Satu Ahomäki

8/12/2024 Managers transactions
Illustration image.png

Orion Group Half-Year Financial Report January–June 2024

8/8/2024 Stock exchange release
Illustration image.png

Orion Corporation’s financial reporting and Annual General Meeting in 2025

8/8/2024 Stock exchange release
Illustration image.png

Orion publishes Half-Year Financial Report for January–June 2024 and holds a webcast on 8 August 2024

7/25/2024 Press release
Illustration image.png

Inside information: Phase III ARANOTE trial of darolutamide in combination with androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer meets primary endpoint

7/17/2024 Stock exchange release
Illustration image.png

Inside information: Orion upgrades full-year outlook for 2024

7/1/2024 Stock exchange release
Illustration image.png

Inside information: Orion and MSD Announce Mutual Exercise of Option Providing MSD Global Exclusive Rights to Opevesostat, an Investigational CYP11A1 Inhibitor, for the Treatment of Metastatic Castration-Resistant Prostate Cancer

7/1/2024 Stock exchange release